Oestrogen and Tumour Types Revision Notes | A Level AQA Biology

1. Why Oestrogen and Tumours Matter at A Level

Every year, breast cancer is diagnosed in around 55,000 people in the UK. A significant proportion of those cases are driven not by a random mutation alone, but by a hormone the body produces naturally: oestrogen. Understanding how a normal signalling molecule can tip cells into uncontrolled division sits right at the heart of the AQA specification on gene expression control.

This lesson connects two spec requirements that examiners frequently combine in the same question: the role of oestrogen in breast cancer development, and the distinction between benign and malignant tumours. Nail both, and you have the tools to answer describe, explain, compare, and evaluate questions on this topic with precision.

2. Oestrogen as a Transcription Factor — The Mechanism

Oestrogen is a steroid hormone, which means it is small and lipid-soluble enough to diffuse directly through the phospholipid bilayer of the cell membrane. Once inside the cell, it binds to a specific intracellular receptor protein called the oestrogen receptor (ER). This binding changes the shape of the receptor, activating it.

The activated oestrogen–receptor complex then moves into the nucleus and binds to specific DNA sequences called oestrogen response elements (EREs), which are located in the promoter regions of target genes. Acting as a transcription factor, the complex recruits RNA polymerase and stimulates transcription of those genes. The proteins produced include cyclins — key regulators of the cell cycle that drive cells from one phase to the next.

Here is the critical link to cancer: when oestrogen concentrations are elevated, the oestrogen–ER complex is formed more frequently and for longer periods. This means target genes — including those encoding cyclins and other pro-proliferative proteins — are transcribed at a higher rate. The result is an increased rate of cell division in oestrogen-sensitive tissues such as breast epithelium.

If mutations are also present in tumour-suppressor genes or proto-oncogenes, the cell's normal checkpoints cannot halt this accelerated division. Cells accumulate further mutations and begin to divide without the usual controls — the starting point of tumour formation. Elevated oestrogen does not cause cancer on its own, but it acts as a powerful promoter of cell proliferation in cells that already carry genetic damage.

This mechanism explains why treatments that block oestrogen receptors — such as tamoxifen — or that reduce oestrogen production are effective in oestrogen receptor-positive (ER+) breast cancers. Removing the transcription factor signal slows the rate of cell division in tumour cells. That is the clinical payoff of understanding this molecular pathway.

3. Tumour Types — Benign vs Malignant

Not all abnormal cell masses behave the same way. The distinction between benign and malignant tumours is one of the most commonly examined comparisons in this topic, and examiners expect precise language — not vague descriptions like 'bad' or 'dangerous'.

A benign tumour grows as a self-contained mass. Because it is encapsulated, it pushes neighbouring tissues aside rather than infiltrating them. This makes surgical removal straightforward in most cases, and the tumour rarely returns. A common example is a lipoma — a benign fatty lump under the skin.

A malignant tumour is fundamentally different in behaviour. Its cells have lost the adhesion molecules that keep normal cells anchored in place, allowing them to break away from the primary tumour. These cells can enter blood vessels or lymphatic vessels and travel to distant sites — a process called metastasis — where they seed secondary tumours. It is metastasis, not the primary tumour alone, that makes malignant cancer so difficult to treat.

4. Oestrogen and Breast Cancer — Connecting the Mechanism to the Disease

Recall from Section 2 that oestrogen drives transcription of pro-proliferative genes. Now apply that to breast tissue specifically. Breast epithelial cells express high levels of oestrogen receptors, making them particularly sensitive to circulating oestrogen. When oestrogen concentrations are chronically elevated — for example, due to obesity (adipose tissue synthesises oestrogen), early menarche, late menopause, or hormone replacement therapy — these cells receive a sustained signal to divide.

Each additional cell division is an opportunity for a replication error. Over time, mutations accumulate in genes controlling the cell cycle. If a mutation inactivates a tumour-suppressor gene such as BRCA1 or activates a proto-oncogene, the cell loses its normal brakes on division. Combined with the oestrogen-driven acceleration of the cell cycle, this produces a cell population that divides rapidly and without restraint — a malignant tumour.

Approximately 70–80% of breast cancers are ER-positive, meaning the tumour cells express functional oestrogen receptors and their growth is oestrogen-dependent. This is why measuring ER status is a standard part of breast cancer diagnosis: it directly informs treatment. ER-positive tumours respond to anti-oestrogen therapies; ER-negative tumours do not, and require different treatment strategies.

5. Applying the Knowledge — Exam-Style Walkthrough

Exam questions on this topic often ask you to explain a mechanism, compare tumour types, or evaluate evidence. The step-by-step below models how to construct a high-quality 'explain' response — the type that earns all available marks rather than just the first one.

Worked example: Constructing an Explain Answer: Oestrogen and Breast Cancer

Explain how increased oestrogen concentrations can lead to the development of a malignant breast tumour. [5 marks]

1. Oestrogen diffuses through the cell membrane and binds to intracellular oestrogen receptors, forming an oestrogen–receptor complex. — [B1] — Establishes the mechanism. Many students skip this step and lose the first mark.
2. The complex enters the nucleus and binds to oestrogen response elements in the promoter regions of target genes, acting as a transcription factor to increase transcription. — [B1] — Must name the promoter region or oestrogen response element for full credit. Vague answers such as 'binds to DNA' are insufficient.
3. Increased transcription of genes encoding cyclins and other cell-cycle regulators accelerates progression through the cell cycle, increasing the rate of cell division in breast epithelial cells. — [B1] — Naming cyclins or cell-cycle regulators strengthens this mark. The link between transcription and division rate must be explicit.
4. More frequent cell divisions increase the probability of DNA replication errors; mutations may accumulate in tumour-suppressor genes or proto-oncogenes. — [B1] — The word 'probability' is important here. Oestrogen does not cause mutations directly; it increases the chance of them occurring.
5. If mutations remove normal cell-cycle checkpoints, cells divide uncontrollably, invade surrounding tissue, and may metastasise — forming a malignant tumour. — [B1] — Must include invasion or metastasis to distinguish malignant from benign. A response that only mentions 'uncontrolled division' without these features will not score this mark.

Answer: A complete 5-mark response links: oestrogen binding to receptor → transcription factor action at promoter → increased cyclin transcription → accelerated cell division → accumulation of mutations → loss of cell-cycle control → malignant tumour with invasion and metastasis.

6. Comparing Tumour Types — Exam Technique

When a question uses the command word 'compare', you must address both similarities and differences. A common error is to describe each tumour type separately without ever using comparative language. Examiners award marks for explicit comparison, not for two parallel descriptions placed next to each other.

When a question uses the command word 'compare', you must address both similarities and differences. A common error is to describe each tumour type separately without ever using comparative language. Examiners award marks for explicit comparison, not for two parallel descriptions placed next to each other.\n\nAlthough both benign and malignant tumours arise from abnormal cell division, only malignant tumours have truly uncontrolled, unlimited proliferation. Benign tumours are self-limiting and encapsulated, meaning their growth remains localised and under some regulatory control, while malignant tumours escape these controls entirely.

One further distinction worth committing to memory: benign tumour cells retain relatively normal differentiation, meaning they still resemble the tissue of origin. Malignant cells are often poorly differentiated — they have lost the specialised features of the original cell type. This loss of differentiation (anaplasia) is one reason malignant tumours grow so aggressively; the cells are no longer performing a specialised function and instead devote resources entirely to division.

7. Exam Technique and Common Mistakes

Questions on this topic appear in both short-answer and extended-response formats. The most reliable way to lose marks is to use imprecise language where the mark scheme demands specific terminology. The guidance below consolidates the highest-yield exam technique points for this topic.

Bringing this together: the AQA specification requires you to connect the molecular mechanism of oestrogen action to the cellular outcome of uncontrolled division, and to distinguish precisely between the two tumour types that can result. Both spec points are regularly examined in the same question, so practise writing responses that move fluently from the transcription factor mechanism through to the characteristics of the resulting tumour.